Q1 Earnings Forecast for BioCardia Issued By HC Wainwright

BioCardia, Inc. (NASDAQ:BCDA) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for BioCardia in a note issued to investors on Thursday, March 26th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.17) per share for the quarter. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.18) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $25.00.

BioCardia Stock Performance

NASDAQ:BCDA opened at $1.16 on Friday. The firm has a 50-day simple moving average of $1.23 and a 200-day simple moving average of $1.34. BioCardia has a one year low of $1.00 and a one year high of $3.20. The firm has a market cap of $12.69 million, a P/E ratio of -0.90 and a beta of 0.60.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.14.

Hedge Funds Weigh In On BioCardia

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cetera Investment Advisers bought a new position in BioCardia in the second quarter worth about $40,000. DRW Securities LLC bought a new stake in shares of BioCardia in the 4th quarter valued at about $72,000. Finally, Geode Capital Management LLC grew its position in shares of BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after buying an additional 27,263 shares during the last quarter. Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.